SERVICE AND SOLUTION

Contract Development Manufacturing Organization (CDMO)

Genepeutic Bio will be the first CDMO that is fully GMP-compliance in Thailand, providing manufacturing services for Chimeric Antigen Receptor (CAR) modified T-cells.

The process involves the use of autologous or allogeneic blood to isolate, activate, and transduce T-cells with proprietary CAR sequences. The transduced T-cells are then expanded and concentrated to obtain a sufficient number of CAR T-cells to infuse to the patients for cancer treatment. As Genepeutic Bio strictly observes the quality of the products, the finished products will undergo extensive release testing before the release to be used in patients.

The GMP-Compliant Facility

In 2012, Thailand Center of Excellence for Life Sciences (TCELS) renovated the existing facility, which was operated by National Science and Technology Development Agency (NSTDA) located at Innovation Cluster II, Thailand Science Park, Pathum Thani, into a GMP Production Unit for Cell and Gene Therapy Products (CPU). This facility is suitable for manufacturing of the cell and gene products with QA/QC processes for safety used in the patient.

In 2020, Genepeutic Bio, with a public & private partnership, invested in the facility to develop and utilize it into a one-stop service center for cell and gene therapy. The facility will be fully operational in the late 2021, which will be fully GMP-compliance and intially serves as a manufacturing site for CAR T-cells products in Thailand.

Our Product

Anti-CD19 CAR T-cells (2nd Generation)

Indications: Relapsed/Refractory CD19 Positive B-cell Malignancies